Dafne Mesa Reynaldo, APRN

Dafne Mesa Reynaldo practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dafne Mesa Reynaldo's NPI, 1487310462, was assigned on November 13, 2021. Dafne Mesa Reynaldo holds Florida license 11016471.

Dafne Mesa Reynaldo's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dafne Mesa Reynaldo's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dafne Mesa Reynaldo practices. Vendor and product names are available with a free account.

Family is Dafne Mesa Reynaldo's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Dafne Mesa Reynaldo is licensed in Florida.

CMS counts 46 Medicare patients who saw Dafne Mesa Reynaldo in 2024. The largest group is 65 to 74, with 19 patients. 75% of them have cancer, and 75% have high blood pressure. 41% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dafne Mesa Reynaldo's median patient age at 64, with 97% women.

In 2024, Dafne Mesa Reynaldo wrote 489 Medicare Part D claims for 148 patients. 89% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dafne Mesa Reynaldo for performance year 2024, reported as part of a group. Dafne Mesa Reynaldo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dafne Mesa Reynaldo as offering telehealth.

CMS Open Payments shows 1 general payment to Dafne Mesa Reynaldo from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $30.